Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1992 Sep;68(803):702–706. doi: 10.1136/pgmj.68.803.702

Review of current and future approaches to the management of benign prostatic hyperplasia.

J C Gingell 1
PMCID: PMC2399459  PMID: 1282714

Full text

PDF
702

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashken M. H., Coulange C., Milroy E. J., Sarramon J. P. European experience with the urethral Wallstent for urethral strictures. Eur Urol. 1991;19(3):181–185. doi: 10.1159/000473615. [DOI] [PubMed] [Google Scholar]
  2. Ashley J. S., Howlett A., Morris J. N. Case-fatality of hyperplasia of the prostate in two teaching and three regional-board hospitals. Lancet. 1971 Dec 11;2(7737):1308–1311. doi: 10.1016/s0140-6736(71)90619-2. [DOI] [PubMed] [Google Scholar]
  3. Ball A. J., Feneley R. C., Abrams P. H. The natural history of untreated "prostatism". Br J Urol. 1981 Dec;53(6):613–616. doi: 10.1111/j.1464-410x.1981.tb03273.x. [DOI] [PubMed] [Google Scholar]
  4. Bosch R. J., Griffiths D. J., Blom J. H., Schroeder F. H. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol. 1989 Jan;141(1):68–72. doi: 10.1016/s0022-5347(17)40591-x. [DOI] [PubMed] [Google Scholar]
  5. Britton J. P., Dowell A. C., Whelan P. Prevalence of urinary symptoms in men aged over 60. Br J Urol. 1990 Aug;66(2):175–176. doi: 10.1111/j.1464-410x.1990.tb14898.x. [DOI] [PubMed] [Google Scholar]
  6. Caine M., Perlberg S., Shapiro A. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urology. 1981 Jun;17(6):542–546. doi: 10.1016/0090-4295(81)90071-6. [DOI] [PubMed] [Google Scholar]
  7. Castaneda F., Reddy P., Wasserman N., Hulbert J., Lund G., Letourneau J. G., Hunter D. W., Castaneda-Zuniga W. R., Amplatz K. Benign prostatic hypertrophy: retrograde transurethral dilation of the prostatic urethra in humans. Work in progress. Radiology. 1987 Jun;163(3):649–653. doi: 10.1148/radiology.163.3.2437611. [DOI] [PubMed] [Google Scholar]
  8. Chapple C. R., Milroy E. J., Rickards D. Permanently implanted urethral stent for prostatic obstruction in the unfit patient. Preliminary report. Br J Urol. 1990 Jul;66(1):58–65. doi: 10.1111/j.1464-410x.1990.tb14866.x. [DOI] [PubMed] [Google Scholar]
  9. Chilton C. P., Morgan R. J., England H. R., Paris A. M., Blandy J. P. A critical evaluation of the results of transurethral resection of the prostate. Br J Urol. 1978 Dec;50(7):542–546. doi: 10.1111/j.1464-410x.1978.tb06208.x. [DOI] [PubMed] [Google Scholar]
  10. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology. 1988 Dec;32(6 Suppl):27–31. [PubMed] [Google Scholar]
  11. Garraway W. M., Collins G. N., Lee R. J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469–471. doi: 10.1016/0140-6736(91)90543-x. [DOI] [PubMed] [Google Scholar]
  12. Gill K. P., Machan L. S., Allison D. J., Williams G. Bladder outflow tract obstruction and urinary retention from benign prostatic hypertrophy treated by balloon dilatation. Br J Urol. 1989 Dec;64(6):618–622. doi: 10.1111/j.1464-410x.1989.tb05321.x. [DOI] [PubMed] [Google Scholar]
  13. Iacovou J. W., Dunn M. Indoramin--an effective new drug in the management of bladder outflow obstruction. Br J Urol. 1987 Dec;60(6):526–528. doi: 10.1111/j.1464-410x.1987.tb05035.x. [DOI] [PubMed] [Google Scholar]
  14. Kirby R. S., Coppinger S. W., Corcoran M. O., Chapple C. R., Flannigan M., Milroy E. J. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol. 1987 Aug;60(2):136–142. doi: 10.1111/j.1464-410x.1987.tb04950.x. [DOI] [PubMed] [Google Scholar]
  15. Lindner A., Golomb J., Siegel Y., Lev A. Local hyperthermia of the prostate gland for the treatment of benign prostatic hypertrophy and urinary retention. A preliminary report. Br J Urol. 1987 Dec;60(6):567–571. doi: 10.1111/j.1464-410x.1987.tb05043.x. [DOI] [PubMed] [Google Scholar]
  16. McLoughlin J., Jager R., Abel P. D., el Din A., Adam A., Williams G. The use of prostatic stents in patients with urinary retention who are unfit for surgery. An interim report. Br J Urol. 1990 Jul;66(1):66–70. doi: 10.1111/j.1464-410x.1990.tb14867.x. [DOI] [PubMed] [Google Scholar]
  17. McNeal J. E. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978 Jan;15(4):340–345. [PubMed] [Google Scholar]
  18. Milroy E. J., Chapple C., Eldin A., Wallsten H. A new treatment for urethral strictures: a permanently implanted urethral stent. J Urol. 1989 May;141(5):1120–1122. doi: 10.1016/s0022-5347(17)41187-6. [DOI] [PubMed] [Google Scholar]
  19. Moore R. J., Gazak J. M., Wilson J. D. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol. J Clin Invest. 1979 Mar;63(3):351–357. doi: 10.1172/JCI109310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nielsen K. K., Klarskov P., Nordling J., Andersen J. T., Holm H. H. The intraprostatic spiral. New treatment for urinary retention. Br J Urol. 1990 May;65(5):500–503. doi: 10.1111/j.1464-410x.1990.tb14795.x. [DOI] [PubMed] [Google Scholar]
  21. Reddy P. K., Wasserman N., Castañeda F., Castañeda-Zuñiga W. R. Balloon dilatation of the prostate for treatment of benign hyperplasia. Urol Clin North Am. 1988 Aug;15(3):529–535. [PubMed] [Google Scholar]
  22. Rohr H. P., Bartsch G. Human benign prostatic hyperplasia: a stromal disease? New perspectives by quantitative morphology. Urology. 1980 Dec;16(6):625–633. doi: 10.1016/0090-4295(80)90577-4. [DOI] [PubMed] [Google Scholar]
  23. Roos N. P., Ramsey E. W. A population-based study of prostatectomy: outcomes associated with differing surgical approaches. J Urol. 1987 Jun;137(6):1184–1188. doi: 10.1016/s0022-5347(17)44442-9. [DOI] [PubMed] [Google Scholar]
  24. Roos N. P., Wennberg J. E., Malenka D. J., Fisher E. S., McPherson K., Andersen T. F., Cohen M. M., Ramsey E. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989 Apr 27;320(17):1120–1124. doi: 10.1056/NEJM198904273201705. [DOI] [PubMed] [Google Scholar]
  25. Sarramon J. P., Joffre F., Rischmann P., Rousseau H., ElDin A. Use of the Wallstent endourethral prosthesis in the treatment of recurrent urethral strictures. Eur Urol. 1990;18(4):281–285. doi: 10.1159/000463929. [DOI] [PubMed] [Google Scholar]
  26. Siiteri P. K., Wilson J. D. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970 Sep;49(9):1737–1745. doi: 10.1172/JCI106391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Singh M., Tresidder G. C., Blandy J. P. The evaluation of transurethral resection for benign enlargement of the prostate. Br J Urol. 1973 Feb;45(1):93–102. [PubMed] [Google Scholar]
  28. Steyn M. Just old age? A study of prostatism in general practice. Fam Pract. 1988 Sep;5(3):193–195. doi: 10.1093/fampra/5.3.193. [DOI] [PubMed] [Google Scholar]
  29. Walsh P. C., Hutchins G. M., Ewing L. L. Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. J Clin Invest. 1983 Nov;72(5):1772–1777. doi: 10.1172/JCI111137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wennberg J. E., Roos N., Sola L., Schori A., Jaffe R. Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. JAMA. 1987 Feb 20;257(7):933–936. [PubMed] [Google Scholar]
  31. Wilson J. D. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980 May;68(5):745–756. doi: 10.1016/0002-9343(80)90267-3. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES